Literature DB >> 24346415

Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection.

Caecilia S Reiner1, Paul Stolzmann, Lars Husmann, Irene A Burger, Martin W Hüllner, Niklaus G Schaefer, Paul M Schneider, Gustav K von Schulthess, Patrick Veit-Haibach.   

Abstract

PURPOSE: To compare the accuracy of PET/MR imaging with that of FDG PET/CT and to determine the MR sequences necessary for the detection of liver metastasis using a trimodality PET/CT/MR set-up.
METHODS: Included in this single-centre IRB-approved study were 55 patients (22 women, age 61 ± 11 years) with suspected liver metastases from gastrointestinal cancer. Imaging using a trimodality PET/CT/MR set-up (time-of-flight PET/CT and 3-T whole-body MR imager) comprised PET, low-dose CT, contrast-enhanced (CE) CT of the abdomen, and MR with T1-W/T2-W, diffusion-weighted (DWI), and dynamic CE imaging. Two readers evaluated the following image sets for liver metastasis: PET/CT (set A), PET/CECT (B), PET/MR including T1-W/T2-W (C), T1-W/T2-W with either DWI (D) or CE imaging (E), and a combination (F). The accuracy of each image set was determined by receiver-operating characteristic analysis using image set B as the standard of reference.
RESULTS: Of 120 liver lesions in 21/55 patients (38%), 79 (66%) were considered malignant, and 63/79 (80%) showed abnormal FDG uptake. Accuracies were 0.937 (95% CI 89.5 - 97.9%) for image set A, 1.00 (95% CI 99.9 - 100.0%) for set C, 0.998 (95% CI 99.4 - 100.0%) for set D, 0.997 (95% CI 99.3 - 100.0%) for set E, and 0.995 (95% CI 99.0 - 100.0%) for set F. Differences were significant for image sets D - F (P < 0.05) when including lesions without abnormal FDG uptake. As shown by follow-up imaging after 50 - 177 days, the use of image sets D and both sets E and F led to the detection of metastases in one and three patients, respectively, and further metastases in the contralateral lobe in two patients negative on PET/CECT (P = 0.06).
CONCLUSION: PET/MR imaging with T1-W/T2-W sequences results in similar diagnostic accuracy for the detection of liver metastases to PET/CECT. To significantly improve the characterization of liver lesions, we recommend the use of dynamic CE imaging sequences. PET/MR imaging has a diagnostic impact on clinical decision making.

Entities:  

Mesh:

Year:  2013        PMID: 24346415     DOI: 10.1007/s00259-013-2654-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  31 in total

Review 1.  Strategies for safer liver surgery and partial liver transplantation.

Authors:  Pierre-Alain Clavien; Henrik Petrowsky; Michelle L DeOliveira; Rolf Graf
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

2.  Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT.

Authors:  C Valls; E Andía; A Sánchez; A Gumà; J Figueras; J Torras; T Serrano
Journal:  Radiology       Date:  2001-01       Impact factor: 11.105

3.  Workflow and scan protocol considerations for integrated whole-body PET/MRI in oncology.

Authors:  Axel Martinez-Möller; Matthias Eiber; Stephan G Nekolla; Michael Souvatzoglou; Alexander Drzezga; Sibylle Ziegler; Ernst J Rummeny; Markus Schwaiger; Ambros J Beer
Journal:  J Nucl Med       Date:  2012-08-09       Impact factor: 10.057

Review 4.  Diffusion-weighted imaging of the liver: a comprehensive review.

Authors:  Lorenzo Mannelli; Puneet Bhargava; Sherif F Osman; Eytan Raz; Mariam Moshiri; Giacomo Laffi; Gregory J Wilson; Jeffrey H Maki
Journal:  Curr Probl Diagn Radiol       Date:  2013 May-Jun

5.  Toward implementing an MRI-based PET attenuation-correction method for neurologic studies on the MR-PET brain prototype.

Authors:  Ciprian Catana; Andre van der Kouwe; Thomas Benner; Christian J Michel; Michael Hamm; Matthias Fenchel; Bruce Fischl; Bruce Rosen; Matthias Schmand; A Gregory Sorensen
Journal:  J Nucl Med       Date:  2010-09       Impact factor: 10.057

6.  Diagnosis of liver metastases: value of diffusion-weighted MRI compared with gadolinium-enhanced MRI.

Authors:  Andrew D Hardie; Mohit Naik; Elizabeth M Hecht; Hersh Chandarana; Lorenzo Mannelli; James S Babb; Bachir Taouli
Journal:  Eur Radiol       Date:  2010-02-11       Impact factor: 5.315

7.  Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions.

Authors:  Matthias Eiber; Axel Martinez-Möller; Michael Souvatzoglou; Konstantin Holzapfel; Anja Pickhard; Dennys Löffelbein; Ivan Santi; Ernst J Rummeny; Sibylle Ziegler; Markus Schwaiger; Stephan G Nekolla; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06-18       Impact factor: 9.236

8.  Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis.

Authors:  Shandra Bipat; Maarten S van Leeuwen; Emile F I Comans; Milan E J Pijl; Patrick M M Bossuyt; Aeilko H Zwinderman; Jaap Stoker
Journal:  Radiology       Date:  2005-08-11       Impact factor: 11.105

9.  Dual-time-point FDG-PET/CT for the detection of hepatic metastases.

Authors:  Albert Dirisamer; Benjamin S Halpern; Wolfgang Schima; Martin Heinisch; Florian Wolf; Mohsen Beheshti; Franz Dirisamer; Michael Weber; Werner Langsteger
Journal:  Mol Imaging Biol       Date:  2008-08-16       Impact factor: 3.488

10.  Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging.

Authors:  Tejas Parikh; Stephen J Drew; Vivian S Lee; Samson Wong; Elizabeth M Hecht; James S Babb; Bachir Taouli
Journal:  Radiology       Date:  2008-01-25       Impact factor: 11.105

View more
  23 in total

Review 1.  [Combined PET-MRI of the abdomen].

Authors:  Tibor Vag; M Eiber; M Schwaiger
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

Review 2.  Functional imaging of hepatocellular carcinoma.

Authors:  Tim Ch Hoogenboom; Mark Thursz; Eric O Aboagye; Rohini Sharma
Journal:  Hepat Oncol       Date:  2016-03-29

3.  Indeterminate Findings on Oncologic PET/CT: What Difference Does PET/MRI Make?

Authors:  Tyler J Fraum; Kathryn J Fowler; Jonathan McConathy; Farrokh Dehdashti
Journal:  Nucl Med Mol Imaging       Date:  2016-02-22

4.  18F-FDG PET/MRI in patients suffering from lymphoma: how much MRI information is really needed?

Authors:  Julian Kirchner; Cornelius Deuschl; Johannes Grueneisen; Ken Herrmann; Michael Forsting; Philipp Heusch; Gerald Antoch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-04       Impact factor: 9.236

Review 5.  FDG Whole-Body PET/MRI in Oncology: a Systematic Review.

Authors:  Hyun Woo Kwon; Ann-Katharina Becker; Jin Mo Goo; Gi Jeong Cheon
Journal:  Nucl Med Mol Imaging       Date:  2016-04-07

6.  Iterative motion-compensation reconstruction ultra-short TE (iMoCo UTE) for high-resolution free-breathing pulmonary MRI.

Authors:  Xucheng Zhu; Marilynn Chan; Michael Lustig; Kevin M Johnson; Peder E Z Larson
Journal:  Magn Reson Med       Date:  2019-09-30       Impact factor: 4.668

Review 7.  18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients.

Authors:  Claudio Spick; Ken Herrmann; Johannes Czernin
Journal:  J Nucl Med       Date:  2016-01-07       Impact factor: 10.057

Review 8.  Clinical applications of PET/MRI: current status and future perspectives.

Authors:  Felix Nensa; Karsten Beiderwellen; Philipp Heusch; Axel Wetter
Journal:  Diagn Interv Radiol       Date:  2014 Sep-Oct       Impact factor: 2.630

9.  Polymer nanoassemblies with solvato- and halo-fluorochromism for drug release monitoring and metastasis imaging.

Authors:  Derek Reichel; Piotr Rychahou; Younsoo Bae
Journal:  Ther Deliv       Date:  2015-10-08

Review 10.  The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis.

Authors:  R Chowdhury; B Ganeshan; S Irshad; K Lawler; M Eisenblätter; H Milewicz; M Rodriguez-Justo; K Miles; P Ellis; A Groves; S Punwani; T Ng
Journal:  Br J Radiol       Date:  2014-03-06       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.